Earlier investigations revealed promising outcomes regarding the potential of NTX to restore TRPM3 function, based on in vitro experiments using NK cells from both ME/CFS and long COVID patients (Cabanas et al., 2019b; Sasso et al., 2024). The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.